New York State Common Retirement Fund Boosts Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

New York State Common Retirement Fund boosted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 18.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 98,097 shares of the biopharmaceutical company’s stock after purchasing an additional 15,239 shares during the quarter. New York State Common Retirement Fund owned about 0.06% of Ocular Therapeutix worth $838,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Creative Planning bought a new stake in shares of Ocular Therapeutix in the third quarter worth about $182,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 1,015 shares in the last quarter. Rosalind Advisors Inc. increased its stake in Ocular Therapeutix by 18.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 885,000 shares of the biopharmaceutical company’s stock worth $7,700,000 after acquiring an additional 135,000 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Ocular Therapeutix during the 3rd quarter worth approximately $70,000. Finally, GSA Capital Partners LLP bought a new position in shares of Ocular Therapeutix during the 3rd quarter valued at approximately $1,102,000. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Trading Down 16.9 %

Shares of OCUL stock opened at $5.93 on Tuesday. The company has a market cap of $932.30 million, a PE ratio of -4.49 and a beta of 1.22. Ocular Therapeutix, Inc. has a 1 year low of $4.06 and a 1 year high of $11.77. The stock’s 50 day simple moving average is $7.89 and its two-hundred day simple moving average is $8.92. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The company had revenue of $17.08 million during the quarter, compared to the consensus estimate of $16.89 million. Research analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Insider Activity

In related news, insider Pravin Dugel sold 21,475 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the sale, the insider now directly owns 3,520,318 shares in the company, valued at $24,184,584.66. This represents a 0.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Donald Notman sold 6,301 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $7.84, for a total transaction of $49,399.84. Following the completion of the sale, the insider now owns 204,563 shares in the company, valued at $1,603,773.92. This represents a 2.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,895 shares of company stock valued at $283,772. 3.50% of the stock is currently owned by insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.